..All patient samples showed a varied degree of sensitivity to BCR-ABL1 inhibitors, with ponatinib being the only BCR-ABL1 inhibitor that was effective in all patient samples (Figure 2). The cells of patient 1 that had an E255K mutation were only sensitive to dasatinib and ponatinib and showed minimal or no effect to other BCR-ABL1 inhibitors (for example, imatinib and nilotinib). Patient 2 had a T315I mutation and hence the patient cells were resistant to all primary BCR-ABL1 inhibitors except ponatinib and axitinib. Cells derived from patient 3 (with no mutation affecting BCR-ABL) were highly sensitive to all BCR-ABL1 inhibitors and the drug response profile resembled that of the TKI-sensitive cell lines (EM-2 and K-562)..
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.